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Figure 2: Relative changes from baseline of the ETP-based nAPCsr in postmenopausal 
women receiving different doses of E4 or placebo
Figure 3: Relative changes from baseline of the ETP-based nAPCsr in premenopausal 
women receiving 15 mg E4/DRSP,  EE 20 µg/DRSP3 mg, or  EE 30 µg/LNG 150 µg [4]
Introduction
Combined oral contraceptives (COC) or hormonal replacement 
therapy (HRT) increase 3 to 6 fold the risk of venous thrombo-
embolism (VTE). This risk increase is largely explained by  induc-
tion by the estrogens of resistance towards the physiological 
anticoagulant called Activated Protein C (APC) [1–3]  (Figure 1) . 
Estetrol (E4) is a promising natural estrogen in development 
by Mithra Pharmaceuticals. Unlike other estrogens, E4 blocks 
the activation of the membrane estrogen receptor α (ERα).This 
property of E4 is the basis for its tissue specific action and its 
unique pharmacodynamic profile. Data in pre- and postmeno- 
pausal women show that E4 alone or in combination with a 
progestin has minimal stimulatory effects on triglycerides, sex 
hormone binding globulin, corticosteroid-binding globulin, and 
angiotensinogen.
In this study, we sought to determine the effects of E4 on the 
resistance to APC in postmenopausal women.
ETP-based nAPCsr
 ■ ETP based APCsr  was determined as described previously [7]. Venous blood was collected 
from the antecubital vein into 0.109 M sodium citrate tubes without corn trypsin inhibitor. 
Platelet poor plasma (PPP) was obtained by centrifugation within 30 minutes of blood with-
drawal. PPP was aliquoted, snap frozen, and subsequently stored in liquid nitrogen.
 ■ Frozen samples were thawed and performed within 4 hours after thawing. The ETP-based 
APC resistance assay was conducted using the Calibrated Automated Thrombogram (CAT) 
and the Thrombinoscope software (Thrombinoscope bv, Maastricht, the Netherlands).
 ■ Concentration of APC was 
calculated to ensure 90% 
inhibition of ETP (equation 1)  
on reference plasma. 
ETP-based APCr was also 
expressed as the nAPCsr 
according to equation 2. 
APCsr is defined as the ratio of ETP in the presence and absence of exogenous APC in the 
respective plasma sample, divided by the same ratio of a control plasma.
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Figure 1: Protein C Anticoagulant Pathway 
Thrombin (T), once activated by the extrinsic or intrinsic pathways of the coagulation, binds 
to its receptor thrombomodulin on the intact cell surface. As a result, this complex loses the 
procoagulant properties of thrombin and instead becomes a potent activator of protein C. 
APC will then form with protein S a complex that functions as a circulating anticoagulant, 
which specifically degrades and inactivates the phospholipid-bound factors Va and VIIIa. This 
effectively down-regulates the coagulation process and limits clot extension..  
 
T = Thrombin, PC = Protein C, APC = Activated Protein C, PS = Protein S
nAPCsr =    
sample ETP (+APC) / sample ETP (–APC)
Reference plasma  ETP (+APC) / Reference plasma  ETP (–APC)
[Equation 2]
Inhibitation % = (1 –    ) x 100 sample ETP (+APC)sample ETP (–APC) [Equation 1]
Design and methods
 ■ Multicenter, randomized, placebo-controlled, double-blind, dose-finding study
 ■ 257 postmenopausal women 
 ■ 2.5, 5, 10, or 15 mg E4; or placebo once daily for 12 weeks
 ■ Assessments: changes from baseline of coagulation factors, hemostasis biomarkers, and 
ETP-based normalized APC sensitivity ratio (nAPCsr)
The global clotting capacity of plasma called the endogenous thrombin potential (ETP), is 
determined with the thrombin generation test (TGT). The TGT quantifies thrombin generation 
after triggering the extrinsic pathway of the coagulation using tissue factor in presence of phos-
pholipids. To assess APC resistance with this test, the amounts of thrombin generated in the 
absence and presence of exogenous APC are compared. The concentration of APC added to 
plasma is chosen to obtain 90% inhibition of the ETP in individuals not taking COCs, HRT, nor 
having thrombotic abnormalities. Resistance to APC induced by COCs and/or HRT reduces the 
percentage inhibition of the ETP by APC. The relative resistance of the patient’s plasma is then 
compared to that of a reference plasma. This is the basis of the well-known ETP-based nor- 
malized APC sensitivity ratio (nAPCsr).
Results
 ■ No change from baseline 
in any of the hemostasis 
markers including fibrinogen, 
prothrombin, prothrombin 
fragment 1+2, D-dimer, 
factor VIII activity, protein C, 
antithrombin, and tissue factor 
pathway inhibitor
 ■ Non-clinically meaningful, but 
statistically significant, small 
decrease of free protein S 
(5.9%) at the highest E4 dose 
 ■ Relative changes from base-
line of the ETP-based nAPCsr 
are displayed in (Figure 2) 
 ■ The similar relative change 
with E4 15 mg in postmeno-
pausal women was compa-
rable to the increase observed 
in younger women receiving 
E4 15 mg/DRSP 3 mg, but 
is in marked contrast to the 
increases on EE 20 µg/DRSP  
3 mg (219%) and  EE 30 µg /
LNG 150 µg (165%) (Figure 3)
Conclusions
 ■ The observed hemostasis changes with E4 and E4/DRSP in the old and younger populations 
included in postmenopausal and contraceptive trials can be considered as clinically  
non-significant. These hemostasis changes were less than those observed with other  
HRT products containing estradiol or conjugated equine estrogens 
 ■ These data on ETP-based nAPCsr and the other hemostasis data from previous trials 
support the notion that E4 may be associated with a lower risk of thrombosis, strengthening 
the position of E4 as a promising new treatment option for postmenopausal women
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